Cargando…

Evaluation of the safety and immunogenicity of subcutaneous HX575 epoetin alfa in the treatment of anemia associated with chronic kidney disease in predialysis and dialysis patients

Aim: To assess the safety and immunogenicity of subcutaneous (SC) HX575 (epoetin-α) in dialysis- and nondialysis-dependent adult patients with chronic kidney disease (CKD). Methods: Open-label, single-arm, multicenter study in patients (n = 416) from Germany, Italy, Poland, Romania, Russia, Turkey,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casadevall, Nicole, Dobronravov, Vladimir, Eckardt, Kai-Uwe, Ertürk, Sehsuvar, Martynyuk, Liliya, Schmitt, Susanne, Schaffar, Gregor, Rudy, Anita, Krendyukov, Andriy, Ode, Marité
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dustri-Verlag Dr. Karl Feistle 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5607454/ https://www.ncbi.nlm.nih.gov/pubmed/28766493 http://dx.doi.org/10.5414/CN109159

Ejemplares similares

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial
por: Sörgel, Fritz, et al.
Publicado: (2009)

Long-term treatment with biosimilar epoetin-α (HX575) in hemodialysis patients with renal anemia: real-world effectiveness and safety in the MONITOR-CKD5 study
por: London, Gérard, et al.
Publicado: (2018)

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017)

Comparison of the Pharmacokinetic and Pharmacodynamic Profiles of One US-Marketed and Two European-Marketed Epoetin Alfas: A Randomized Prospective Study
por: Lissy, Michael, et al.
Publicado: (2012)

Randomized Controlled Trial of Subcutaneous Epoetin Alfa-epbx Versus Epoetin Alfa in End-Stage Kidney Disease
por: Fishbane, Steven, et al.
Publicado: (2019)

Economic Benefits of Switching From Intravenous to Subcutaneous Epoetin Alfa for the Management of Anemia in Hemodialysis Patients
por: Prasad, Bhanu, et al.
Publicado: (2020)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Epoetin Alfa: A Cause of Coronary Artery Thrombosis
por: Siddiqui, Muhammad Umer, et al.
Publicado: (2017)

Anaemia management with subcutaneous epoetin delta in patients with chronic kidney disease (predialysis, haemodialysis, peritoneal dialysis): results of an open-label, 1-year study
por: Frei, Ulrich, et al.
Publicado: (2009)

Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of Immunogenicity
por: Seidl, Andreas, et al.
Publicado: (2011)

Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease
por: Bartnicki, Piotr, et al.
Publicado: (2013)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Critical Role of Iron in Epoetin Alfa Treatment of Chemotherapy-Associated Anemia
por: Gross, Irwin, et al.
Publicado: (2016)

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon(®) and Eprex(®) following a single subcutaneous administration in healthy male volunteers
por: Yoon, Sumin, et al.
Publicado: (2017)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report
por: Behler, Caroline M, et al.
Publicado: (2009)

Comparative Safety of Originator and Biosimilar Epoetin Alfa Drugs: An Observational Prospective Multicenter Study
por: Stoppa, Giovanna, et al.
Publicado: (2018)

Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study
por: Santos, E.J.F., et al.
Publicado: (2018)

Darbepoetin Versus Epoetin Alfa for the Correction of Anemia in Cancer Patients Receiving Radiotherapy or Chemoradiotherapy Treatment
por: Ots, Pilar Ma Samper, et al.
Publicado: (2008)

Surgical prescription of epoetin alfa in contemporary total hip arthroplasty: a prospective comparative study
por: Hourlier, Hervé, et al.
Publicado: (2019)

Successful Prolonged Desensitization to Epoetin-Alfa Hypersensitivity in an Adult Patient With Advanced Chronic Kidney Disease
por: Panchal, Hemali, et al.
Publicado: (2023)

Epoetin alfa in platinum-treated ovarian cancer patients: results of a multinational, multicentre, randomised trial
por: Wilkinson, P M, et al.
Publicado: (2006)

TSAT is a better predictor than ferritin of hemoglobin response to Epoetin alfa in US dialysis patients
por: Gaweda, Adam E, et al.
Publicado: (2014)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
por: Moebus, Volker, et al.
Publicado: (2013)

Arterial and venous thrombosis complicating coronary artery bypass grafting after use of epoetin alfa-epbx
por: Murillo-Berlioz, Alejandro, et al.
Publicado: (2020)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Breaking the HxNy outbreak
por: Manikandan, Jayapal, et al.
Publicado: (2010)

Optimal predialysis care
por: Sijpkens, Yvo W. J., et al.
Publicado: (2008)

Budget Impact Analysis of Darbepoetin Alfa Every 3 Weeks versus Epoetin Alfa Every Week for Cancer Patients with Anemia due to the Effect of Concomitant Myelosuppressive Chemotherapy
por: McGarvey, November, et al.
Publicado: (2015)

Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)

Long-term Safety of Epoetin Alfa-epbx for the Treatment of Anemia in ESKD: Pooled Analyses of Randomized and Open-label Studies
por: Wish, Jay B., et al.
Publicado: (2019)

Cardiovascular effects of hemoglobin response in patients receiving epoetin alfa and oral iron in heart failure with a preserved ejection fraction
por: Vullaganti, Sirish, et al.
Publicado: (2014)

Population Pharmacodynamic Modeling of Epoetin Alfa in End‐Stage Renal Disease Patients Receiving Maintenance Treatment Using Bayesian Approach
por: Nguyen, Ly Minh, et al.
Publicado: (2020)

Mozart Streichquartette KV421 & 575
por: Mozart, Wolfgang Amadeus, 1756-1791

Higher‐risk myelodysplastic syndrome in an elderly patient: Long‐term partial remission with low‐dose prednisone, G‐CSF, and epoetin alfa
por: Islam, Anwarul
Publicado: (2021)

Thermal Properties of Bayfol(®) HX200 Photopolymer
por: Blanche, Pierre-Alexandre, et al.
Publicado: (2020)

Efficacy and safety of darbepoetin alfa injection replacing epoetin alfa injection for the treatment of renal anemia in Chinese hemodialysis patients: A randomized, open‐label, parallel‐group, noninferiority phase III trial
por: Liu, Bicheng, et al.
Publicado: (2022)

How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy?
por: Hasegawa, Takahiro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1s4qvj94ffe8nsu3b2ev4jtods